Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

LTRN stock hub

Lantern Pharma Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

LTRNis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

23.5M

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

LTRN

In the news

Latest news · LTRN

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROE-123.5

P25 -105.6P50 -46.5P75 -3.1

ROIC-80.1

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All LTRN market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

174

Groups with data

Currency

USD

Showing 174 of 174 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001763950
Company name	Lantern Pharma Inc.
Country	United States
Country code	US
Cusip	51654W101
Employees	16
Employees Change	-8%
Employees Change Percent	-33.33
Enterprise value	$13.5M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2020-06-11
Isin	US51654W1018
Last refreshed	2026-05-10
Market cap	$23.5M
Market cap category	Nano-Cap
Price	$2.1
Price currency	USD
Sector	Healthcare
Sic	2834
Symbol	LTRN
Website	https://www.lanternpharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-72.73%
FCF yield	-66.61%
P/B ratio	3.62x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Net Income	$-17.1M
Net Income Growth Quarters	4%
Net Income Growth Years	1%
Profit Per Employee	$-1.1M
ROA	-61.39
Roa5y	-30.45
ROCE	-275.1
ROE	-123.5
Roe5y	-54.56
ROIC	-80.13

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	-51.64%
Cagr3y	-25.16%
Cagr5y	-33.06%
EPS Growth Quarters	4
EPS Growth Years	1
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	$11M
Cash	$10.1M
Current Assets	$10.8M
Current Liabilities	$4.5M
Debt	$78,539
Debt Equity	$0.01
Equity	$6.5M
Liabilities	$4.5M
Long Term Assets	$232,639
Long Term Liabilities	$0
Net Cash	$10M
Net Cash By Market Cap	$42.66
Net Cash Growth	-57.76%
Net Debt Equity	$-1.54
Tangible Book Value	$6.5M
Tangible Book Value Per Share	$0.58
WACC	15.75

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	2.4
Net Working Capital	$-3.7M
Quick ratio	2.25
Working Capital	$6.3M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-1.26%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	-51.61%
200-day SMA	3.38
3Y total return	-58.08%
50-day SMA	2.24
50-day SMA vs 200-day SMA	50under200
5Y total return	-86.56%
All Time High	24.84
All Time High Change	-91.55%
All Time High Date	2020-10-12
All Time Low	1.11
All Time Low Change	89.19%
All Time Low Date	2026-03-27
ATR	0.26
Beta	2.1
Beta1y	2.9
Beta2y	2.33
Ch YTD	-30.69
High	2.15
High52	5.74
High52 Date	2025-08-06
High52ch	-63.44%
Low	2.04
Low52	1.11
Low52 Date	2026-03-27
Low52ch	89.19%
Ma50ch	-6.25%
Premarket Change Percent	3.43
Premarket Price	$2.11
Premarket Volume	352
Price vs 200-day SMA	-37.83%
RSI	46.26
RSI Monthly	40.54
RSI Weekly	41.44
Sharpe ratio	-0.3x
Sortino ratio	-0.34
Total Return	-1.26%
Tr YTD	-30.69
Tr1m	19.32%
Tr1w	-0.94%
Tr3m	-20.45%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Earnings EPS Estimate	$-0.36
Operating Income	$-18M

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	8,533,107%
Float Percent	76.13%
Shares Insiders	3.26%
Shares Institutions	11.7%
Shares Out	11,208,938
Shares Qo Q	4.47%
Shares Yo Y	1.26%
Short Float	20.4%
Short Ratio	1.21
Short Shares	15.53

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-16.7M
Average Volume	238,382.1x
Bv Per Share	0.58
CAPEX	$-1,715
Ch1m	19.32
Ch1w	-0.94
Ch1y	-51.61
Ch3m	-20.45
Ch3y	-58.08
Ch5y	-86.56
Ch6m	-38.6
Change	2.94%
Change From Open	1.94
Close	2.04
Days Gap	0.98
Depreciation Amortization	17,280
Dollar Volume	247,821
Earnings Date	2026-05-14
Earnings Time	bmo
EBIT	$-18M
EBITDA	$-18M
EPS	$-1.57
F Score	1
FCF	$-15.7M
FCF EV Yield	-116.15x
FCF Per Share	$-1.4
Financing CF	1,498,240
Fiscal Year End	December
Founded	2,013
Investing CF	11,057,073
Ipr	-86
Iprfo	-85.81
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-03-30
Last Report Date	2025-12-31
Last Split Type	Never
Last10k Filing Date	2026-03-30
Ma150	3.06
Ma150ch	-31.42%
Ma20	2.32
Ma20ch	-9.52%
Net CF	-3,088,241
Next Earnings Date	2026-05-22
Open	2.06
Optionable	Yes
Position In Range	55.05
Ppne	107,470
Pre Close	2.04
Price Date	2026-05-08
Ptbv Ratio	3.6
Relative Volume	0.5x
Share Based Comp	1,017,777
Tr6m	-38.6%
Us State	Texas
Volume	118,010

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does LTRN pay a dividend?

Capital-return profile for this ticker.

Performance

LTRN stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns LTRN?

Insider, institutional, and short-interest positioning.

Institutional ownership

+11.7%

Float: +76.1% of shares outstanding

Insider ownership

+3.3%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

LTRN momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

46.3

Neutral momentum band

Price vs 200-day MA

-37.8%

50/200-day relationship not available

Beta (5Y)

2.10

More volatile than the market

Sharpe ratio

-0.30

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About LTRN

Hub-level FAQ points readers to the deeper analysis pages.

What is the current LTRN stock rating?

Lantern Pharma Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full LTRN analysis?

The full report lives at /stocks/LTRN/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for LTRN?

The latest report frames LTRN around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the LTRN page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.